Loan Hoang-Sayag
Director/Board Member bei Orano Med SAS
Profil
Loan joined the Andera Life Sciences team of Andera Partners in November 2018.
Hemato-Oncologist by training, she began her career as Head of Clinic in 1995 at the Hospital Necker in Paris.
She joined the pharmaceutical industry in 2000, first at Roche, then at the Pierre Fabre Research Institute in Boulogne.
She then worked from 2005 to 2015 at Quintiles where she led the Oncology-Hematology medical team for Europe and Latin America.
Before joining Andera Partners, she held positions as Chief Medical Officer at Cellectis and Median Technologies.
Within Andera, her mission is to identify new potential investment opportunities, to assist the investment team in setting up investment operations and in monitoring portfolio companies.
Loan is a graduate of Pierre and Marie Curie University - Paris VI (Doctorate in Medicine, DES in Hematology, DESC in Oncology, DEA in Virology) and ESSEC Business School.
Aktive Positionen von Loan Hoang-Sayag
| Unternehmen | Position | Beginn |
|---|---|---|
Andera Partners SCA
 Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Private Equity Investor | 01.11.2018 |
Orano Med SAS
 Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The private company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | Director/Board Member | - |
Ehemalige bekannte Positionen von Loan Hoang-Sayag
| Unternehmen | Position | Ende |
|---|---|---|
| CELLECTIS S.A. | Chief Tech/Sci/R&D Officer | 05.10.2017 |
| MEDIAN TECHNOLOGIES | Chief Tech/Sci/R&D Officer | - |
Quintiles Transnational Corp.
 Quintiles Transnational Corp. Miscellaneous Commercial ServicesCommercial Services Quintiles Transnational Corp. provides biopharmaceutical development and commercial outsourcing services. It offers product development and integrated healthcare services, including commercial and observational solutions. The company was founded by Dennis B. Gillings and Gary Koch in September 1990 and is headquartered in Durham, NC. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Loan Hoang-Sayag
| Sorbonne Université | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CELLECTIS S.A. | Health Technology |
| MEDIAN TECHNOLOGIES | Health Services |
| Private Unternehmen | 3 |
|---|---|
Quintiles Transnational Corp.
Quintiles Transnational Corp. Miscellaneous Commercial ServicesCommercial Services Quintiles Transnational Corp. provides biopharmaceutical development and commercial outsourcing services. It offers product development and integrated healthcare services, including commercial and observational solutions. The company was founded by Dennis B. Gillings and Gary Koch in September 1990 and is headquartered in Durham, NC. | Commercial Services |
Andera Partners SCA
Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Finance |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The private company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | Health Technology |
